Fibrosis Improved With Hepatitis C Vaccine, Innogenetics Reports
- Fibrosis Improved With Hepatitis C Vaccine, Innogenetics Reports
BRUSSELS (Reuters) Mar 25 - Belgian biotech company Innogenetics said
on Thursday that patients given its hepatitis C experimental vaccine
showed significantly improved liver fibrosis after a 3-year test
Innogenetics said in a statement that "liver fibrosis on average
showed significant improvement compared to baseline" in 23 patients
over a three-year period after four course of vaccine injections.
Eighty-seven percent of the patients either improved or remained
stable in the liver fibrosis score.
The company, which also develops test kits for such viruses as HIV,
already reported positive results in October 2002 based on two
vaccination courses followed by liver biopsy.
"These three-year study results now show that HCV E1 vaccination was
very well tolerated and suggest that such treatment not only halts
disease progression towards liver cirrhosis, but also results in
fibrosis regression over the longer term," Professor F. Nevens, the
principal investigator in the phase IIa clinical study, said in a
Do you Yahoo!?
Yahoo! Finance Tax Center - File online. File on time.